Müller-Tegethoff K, Kasper P, Müller L
Federal Institute for Drugs and Medical Devices, Berlin, Germany.
Mutat Res. 1995 Dec;335(3):293-307. doi: 10.1016/0165-1161(95)00033-x.
Based on a previous study with 8 chemicals (Müller et al., 1993) the applicability of the in vitro rat hepatocyte micronucleus assay was evaluated by testing a further 21 compounds of different chemical classes. The obtained results are in good agreement with the known genotoxic profiles of about 90% of the in total tested compounds. Several known mutagens and carcinogens, i.e., alkylating agents, aromatic amines, nitrosamines, nitro compounds, cross-linking agents, and pyrrolizidine alkaloids gave clear positive results in this assay, whereas all of the tested non-carcinogens were negative. The hepatocyte micronucleus assay was shown to distinguish between carcinogenic/non-carcinogenic isomers, such as 2- and 4-acetylaminofluorene (AAF) and 2- and 1-nitropropane (NP). Furthermore, the non-genotoxic nature of several hepatocarcinogens, i.e., the peroxisome proliferating agents fenofibrate, nafenopin, Wy-14,643, diethyl(hexyl)phthalate (DEHP), and the sedative phenobarbital, could be confirmed in this assay. The hepatocarcinogen coumarin exerted mitogenic but no mutagenic properties in the rat hepatocyte micronucleus assay. This compound may act as a liver tumor promoter. Benzo[a]pyrene (B[a]P) and 7,12-dimethylbenzanthacene (DMBA), both belonging to the group of known carcinogenic and mutagenic polycyclic aromatic hydrocarbons, failed to induce micronucleus formation in rat hepatocytes. The high susceptibility of in vitro proliferating hepatocytes to mitotic inhibition, exerted by the strong cytotoxic actions of these compounds, seems to be responsible for these negative results. A strongly reduced mitotic activity can prevent the formation of micronuclei, even when clastogenic effects may have occurred. In the present stage, the in vitro rat hepatocyte micronucleus assay cannot be recommended for screening genotoxicity testing. It should rather be used for special purposes, e.g., when liver-specific mutagenic effects are expected.
基于之前对8种化学物质的研究(Müller等人,1993年),通过对另外21种不同化学类别的化合物进行测试,评估了体外大鼠肝细胞微核试验的适用性。所得结果与约90%受试化合物的已知遗传毒性特征高度一致。几种已知的诱变剂和致癌物,即烷基化剂、芳香胺、亚硝胺、硝基化合物、交联剂和吡咯里西啶生物碱,在该试验中给出了明确的阳性结果,而所有受试的非致癌物均为阴性。肝细胞微核试验能够区分致癌/非致癌异构体,如2-和4-乙酰氨基芴(AAF)以及2-和1-硝基丙烷(NP)。此外,几种肝癌致癌物,即过氧化物酶体增殖剂非诺贝特、萘夫平、Wy-14,643、邻苯二甲酸二(2-乙基己基)酯(DEHP)以及镇静剂苯巴比妥的非遗传毒性性质,在该试验中得到了证实。肝癌致癌物香豆素在大鼠肝细胞微核试验中表现出促有丝分裂但无诱变特性。该化合物可能作为肝脏肿瘤促进剂起作用。苯并[a]芘(B[a]P)和7,12-二甲基苯并[a]蒽(DMBA)均属于已知的致癌和诱变多环芳烃组,未能在大鼠肝细胞中诱导微核形成。这些化合物的强细胞毒性作用对体外增殖肝细胞产生的有丝分裂抑制的高敏感性,似乎是导致这些阴性结果的原因。即使可能已经发生了断裂效应,强烈降低的有丝分裂活性也会阻止微核的形成。在现阶段,不建议将体外大鼠肝细胞微核试验用于遗传毒性筛选测试。它更应被用于特殊目的,例如当预期有肝脏特异性诱变效应时。